Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-05-14
2009-08-04
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S130100, C424S156100
Reexamination Certificate
active
07569554
ABSTRACT:
The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
REFERENCES:
patent: 5366878 (1994-11-01), Pedersen et al.
patent: 5635377 (1997-06-01), Pedersen et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5912332 (1999-06-01), Agrawal et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6426334 (2002-07-01), Agrawal et al.
patent: 7276489 (2007-10-01), Agrawal et al.
patent: 2001/0034330 (2001-10-01), Kensil
patent: 2002/0132995 (2002-09-01), Agrawal et al.
patent: WO98/49288 (1998-11-01), None
patent: WO01/12804 (2001-02-01), None
patent: WO 01/83503 (2001-04-01), None
patent: WO 02/026757 (2001-07-01), None
patent: WO01/55370 (2001-08-01), None
patent: WO 0197843 (2001-12-01), None
patent: WO 0226757 (2002-04-01), None
patent: WO 03/035836 (2003-05-01), None
patent: WO 03035836 (2003-05-01), None
Kandimalla et al Bioconjugate Chem., 2002; 13: 966-974.
Kandimalla et al, PNAS, 2003; 100: 14303-14308.
Donnelly et al (Nature Medicine, 2003, 9/11:1354-1356).
DeGruijl et al, Nature Medicine, 1999, 5/10:1124-1125.
Bitton R. J. (Current Opinion in Molecular Therapeutics, 2004, 6/1:17-25).
Weiner J. Leukocyte Biology, 2000; 68: 455-463.
Krieg et al Nature 374:546-549 (1995).
Ballas et al J. Immunology 2001; 167: 4878.
Agrawal et al (Trends in Molecular Medicine, 2002, 8/3:114-120).
Wiesenthal (http://weisenthal.org/feedback. html, Feb. 4, 2002).
Tallarida (Drug Synergism and Dose-effect Analysis, Chapman & Hall/CRC, Boca Raton, 2000, pp. 1-13).
Berenbaum (“Synergy, additivism and antagonism in immunosuppression,” Clin exp Immunol 28:1-18, 1977).
Wooldrige et al. (Blood 1997; 89: 2994-2998).
Herceptin® Package Insert (Dec. 11, 2001).
Kuramoto et al. (1992) Jpn. J. Cancer Res. 83:1128-1131.
Krieg et al. (1995) Nature 374: 546-549.
Liang et al. (1996) J. Clin. Invest. 98: 1119-1129.
Zhao et al. (1996) Biochem. Pharmacol. 51:173-182.
Zhao et al. (1996) Biochem. Pharmacol. 52:1537-1544.
Zhao et al. (1997) Antisense Nucleic Acid Drug Dev. &:495-502.
McCluskie et al. (1998) J. Immunol. 161:4463-4466.
Moldoveanu et al. (1998) Vaccine 16:1216-124.
Zhao et al. (1999) Bioorg. Med. Chem. Lett. 9:3453-3458.
Zhao et al. (2000) Bioorg. Med. Chem. Lett. 19:1051-1054.
Yu et al. (2000) Bioorg. Med. Chem. Lett. 10:2585-2588.
Kandimalla et al. (2001) Bioorg. Med. Chem. 9:807-813.
Yu et al. (2001) Bioorg. Med. Chem. Lett. 11:2263-2267.
Warren et al., “Synergism Between Cytosine-Guanine Oligodeoxynucleotides and Monoclonal Antibody in the Treatment of Lymphoma”, Seminars in. Oncol. 2002, vol. 29(1)(2). pp. 93-97.
Cheng et al., “Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine”, J. Nat. Cancer Inst. 2003, vol. 95(5), pp. 399-409.
Weigel et al., “CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Mutine Model of Rhabdomyosarcoma”, Clin. Cancer Resear. 2003, vol. 9, pp. 3105-3114.
Kandimalla et al., “A Dinucleotide Motif in Oligonucleotides Shows Potent Immunomodulatory Activity and Overrides Species-Specific Recognition Observed with CpG Motif”, PNAS 2003, vol. 100(24), pp. 14303-14308.
Agrawal Sudhir
Bhagat Lakshmi
Kandimalla Ekambar R.
Wang Daqing
Yu Dong
Fetterolf Brandon J
Idera Pharmaceuticals Inc.
Keown Wayne A.
Keown & Zucchero, LLP
Zucchero Joseph C.
LandOfFree
Synergistic treatment of cancer using immunomers in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic treatment of cancer using immunomers in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic treatment of cancer using immunomers in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085212